Hence, the observation that the MEK inhibitor trametinib was also able to induce tumor regressions in HRAS-, NRAS-, and RASA1-mutated squamous NSCLC PDXs, in parallel to KRAS-mutated ADC PDXs (Figure 3), supports the enlargement of the number of NSCLC patients who could benefit from treatments including an MEK inhibitor and, consequently, appears to be of high clinical interest. Here, MAP2K7 is linked to neoplasm.